ArticleMetabolic brain disease2025
Elucidating the material basis and therapeutic mechanisms of Shaoma Zhijing granules for tourette syndrome by UPLC/Q-TOF-MS and multiple models.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The potential role of aberrant microglial synaptic pruning in the neurodevelopmental pathogenesis of tourette syndrome.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Tourette syndrome (TS), predominantly affecting children and adolescents aged 2-15 years, significantly impairs quality of life and social functioning. Shaoma Zhijing granules (SMZJG), a compound traditional Chinese medicine (TCM), has demonstrated comparable efficacy to tiapride (TIA) in alleviating TS symptoms with fewer adverse effects. To elucidate its tmaterial basis and mechanism of action, we employed iminodipropionitrile (IDPN) and 2, 5-dimethoxy-4-iodoarylamine (DOI) to induce a rat model of TS. SMZJG treatment significantly ameliorated IDPN- and DOI-induced stereotyped behavioral impairments and effectively counteracted the reduction in striatum volume. Notably, SMZJG was found to markedly correct neurotransmitter imbalances, suppress M1 microglial activation, and reduce the levels of interleukin-1α (IL-1α), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and monocyte chemoattractant protein-1 (MCP-1) in serum. These findings collectively suggest that SMZJG alleviates TS-associated behavioral disorders, potentially through mechanisms such as reducing striatal atrophy, modulating neurotransmitter imbalances, regulating abnormal neurotransmitter receptor expression, and decreasing microglial proliferation as well as levels of pro-inflammatory cytokines and chemokines in serum.
Indexed as
Identifiers
41288886What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.